Cargando…
RIPK2: a promising target for cancer treatment
As an essential mediator of inflammation and innate immunity, the receptor-interacting serine/threonine-protein kinase-2 (RIPK2) is responsible for transducing signaling downstream of the intracellular peptidoglycan sensors nucleotide oligomerization domain (NOD)-like receptors 1 and 2 (NOD1/2), whi...
Autores principales: | You, Jieqiong, Wang, Ying, Chen, Haifeng, Jin, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266216/ https://www.ncbi.nlm.nih.gov/pubmed/37324457 http://dx.doi.org/10.3389/fphar.2023.1192970 |
Ejemplares similares
-
RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases
por: Honjo, Hajime, et al.
Publicado: (2021) -
Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases
por: Pham, Anh-Tuan, et al.
Publicado: (2023) -
Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022) -
Antidepressant Mechanism of Traditional Chinese Medicine Formula Xiaoyaosan in CUMS-Induced Depressed Mouse Model via RIPK1-RIPK3-MLKL Mediated Necroptosis Based on Network Pharmacology Analysis
por: Yan, Zhi-Yi, et al.
Publicado: (2021) -
Erratum: Advances in RIPK1 kinase inhibitors
Publicado: (2023)